pharma · Advanced Malignant Tumors · Metastatic Pancreatic Ductal Adenocarcinoma
Akeso
Akeso is a pharma organization headquartered in CN. Primary therapeutic focus areas include Advanced Malignant Tumors, Metastatic Pancreatic Ductal Adenocarcinoma, Atopic Dermatitis. NovaPharmaNews links 3 clinical progr
Company details
- Status
- Public
- HQ
- CN
- Founded
- 2012
- Employees
- 112
- Programs
- 3
- Drugs
- 8
- Patents
- 0
Quick answer
Akeso is a pharma organization headquartered in CN. Primary therapeutic focus areas include Advanced Malignant Tumors, Metastatic Pancreatic Ductal Adenocarcinoma, Atopic Dermatitis. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (2), phase 1 (1).
Company snapshot
Akeso, Inc (Akeso; [Chinese](en.wikipedia.org/wiki/Simplified_Chinese): 康方生物; [pinyin](en.wikipedia.org/wiki/Pinyin): Kāngfāng Shēngwù) is a [publicly listed](en.wikipedia.org/wiki/Publicly_listed) Chinese [biopharmaceutical](en.wikipedia.org/wiki/Biopharmaceutical) company that is headquartered in [Zhongshan](en.wikipedia.org/wiki/Zhongshan), [Guangdong](en.wikipedia.org/wiki/Guangdong). It is be
- 3 active pipeline program(s) linked via ClinicalTrials.gov.
- 3 trial update(s) in the last 12 months.
Public regulatory, clinical, patent, and corporate records for Akeso. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- approval
ASCO 2026 Preview: Key Data and Trends in Cancer Research
- approval
ASCO26: Summit, Akeso claim OS victory for ivonescimab in pivotal Chinese study
- approval
ASCO Preview: Akeso's Ivonescimab Under Scrutiny
- approval
Pharma bets on PD-1/VEGF bispecifics: Is lung cancer the wrong target?
Recent coverage
Pharma bets on PD-1/VEGF bispecifics: Is lung cancer the wrong target?
While many drugmakers are focused on lung cancer for PD-1/VEGF bispecifics, emerging evidence shows the liver may offer higher value. This analysis covers the mechanism, key players, and strategic implications for pharma teams.
ASCO Preview: Akeso's Ivonescimab Under Scrutiny
As Akeso prepares for a plenary presentation at ASCO 2026, ivonescimab's HARMONi-6 overall survival data will be closely watched. This article covers key takeaways, competitive implications, and next milestones for pharma teams and investors.
ASCO 2026 Preview: Key Data and Trends in Cancer Research
This ASCO preview highlights crucial developments in cancer research, focusing on key data presentations and emerging trends that will shape the oncology landscape. Investors and BD teams should monitor these advancements for strategic insights.
ASCO26: Summit, Akeso claim OS victory for ivonescimab in pivotal Chinese study
Structured plan for ASCO26: Summit, Akeso claim OS victory for ivonescimab in pivotal Chinese study
Top assets
Lead pipeline drugs
- Marketed / approved
- Marketed / approved
- Marketed / approved
- Marketed / approved
Active clinical programs
- Phase 2
- Phase 2
- Phase 1
Momentum signals
Momentum
Proprietary activity score for Akeso.
2 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitive landscape
Recent activity
Recent activity
Latest pipeline, patent, and corporate events for Akeso.
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is Akeso?
-
Is Akeso publicly traded?
-
What drugs does Akeso develop or market?
-
What are the latest developments for Akeso?
-
What therapeutic areas does Akeso focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.